Hemodialysis patients obtain a robust humoral response from a third dose of the BNT162b2 vaccine, study finds

Researchers assessed the humoral immune responses generated by the third Pfizer-BioNTech BNT162b2 mRNA vaccination against SARS-CoV-2 among hemodialysis patients.

Related Keywords

,Centers For Disease ,Pfizer ,Waning Immunity ,Image Credit ,Disease Control ,Coronavirus Disease Covid 19 ,Vaccine ,Ntibody ,Coronavirus ,Covid 19 ,Dialysis ,Immunity ,Kidney ,Kidney Disease ,Ortality ,Protein ,Espiratory ,Ibonucleic Acid ,Cars ,Ars Cov 2 ,Evere Acute Respiratory ,Evere Acute Respiratory Syndrome ,Yndrome ,